ISTH Interim Guidance on Recognition and Management of Coagulopathy in COVID-19

ISTH is recommending the monitoring the following coagulation parameters in assessing the prognosis in COVID-19 patients requiring hospitalisation:

·       Prothrombin time (PT)

·       D-dimer, markedly increased D-dimer is associated with high mortality in COVID-19 patients

·       Fibrinogen

·       Platelet Count

The guidance further states “inhibiting thrombin generation may have benefit in reducing mortality.”  “The only widely available treatment in this respect is prophylactic dose low molecular weight heparin (LMWH) which should be considered in all patients (including non-critically ill) who require hospital admission for COVID-19 infection.”

As a supplier of routine and specialty coagulation reagents and test kits, we offer the following products for meeting the ISTH guidance:

·       QuikCoag™ PT-HS for measuring Prothrombin Time

·       DIMERTEST® Latex for measuring D-dimer

·       IMUCLONE™ D-dimer ELISA for measuring D-dimer

·       QuikCoag™ Fibrinogen Kit

·       ACTICHROME® Heparin (Anti-FXa) for monitoring LMW heparin levels